The post-traumatic stress disorder treatment market size is estimated to be USD 997.54 million in 2022 and is expected to witness a CAGR of 4.95% during the forecast period 2023-2033. Strong late-stage product pipelines, growing demand for better treatment choices and rising R&D for the creation of novel treatment therapies are factors contributing to the market growth. Furthermore, increase in post-traumatic stress disorder (PTSD) cases around the world and rise in prevalence of post-traumatic stress disorder However, high price of therapy is expected to hinder the growth.

Rise in prevalence of post-traumatic stress disorder is expected to propel the market growth during the projected period. One in 13 persons will experience post-traumatic stress disorder at some point in their lives due to the rise in its prevalence. 70% of adult Americans experience at least one traumatic event, and 20% of those people continue to develop PTSD as a result, according to an NCBI study. Since sexual assault and rape victims are the main cause of traumatic events, women are more likely than men to suffer from this disorder. Approximately 9.7% of women and 3.6% of men have it, respectively.

Growing demand for better treatment choices is predicted to fuel the market growth during the forecast period. A lucrative potential for market growth is being formed during the forecast period as a consequence of the growing demand for better treatment choices driving R&D innovation and the introduction of new therapeutic medications. For instance, the Brexpiprazole and Zoloft Combination from Otsuka Pharmaceutical Development Inc. is currently undergoing phase 3 research for PTSD. Furthermore, the phase 2 clinical trials for Jazz Pharmaceuticals’ JZP150, Aptinyx’s NYX-783, and Bionomics’ BNC210 are expected to drive the expansion of the market during the projection period.

Segmentation

By Drug Class

The market is categorized into antipsychotics, antidepressants, anti-anxiety, and others. In 2022, the antidepressants segment accounted for the highest revenue share due to the fact that FDA-approved SSRIs (selective serotonin reuptake inhibitors) driving the space, including Sertraline (Zoloft) and Paroxetine (Paxil). They are advised as the initial course of treatment for PTSD. Serzone (nefazodone), Nardil (phenelzine), and Tofranil (imipramine), some off-label antidepressants with a high presence in the area to treat the disease. In addition, major players are proactively launching projects including partnerships, expansion, and collaborations to create pharmaceuticals and advance in the industry. For instance, H. Lundbeck A/S and Sun Pharmaceutical Industries Ltd. agreed into a licence agreement in March 2022 for the antidepressant medication Vortioxetine. The main players are also working on and developing combination therapy, such as antidepressant drugs, to treat the disease. For instance, the phase 3 trials for the Brexpiprazole and Zoloft Combination by Otsuka Pharmaceutical are expected to propel the market.

By Demographics

The market is categorized into geriatric, pediatric, and adult. In the global market, the adult segment accounted for the largest revenue share in 2022 owing to majority of patients falling into this age group, rise in disorder cases among adults, and surge in traumatic experiences. The majority of the population exhibits severe, moderate, or mild symptoms of impairment. The research study estimates that in the United States in 2021, mild impairment impacted approximately 30% of patients, substantial impairment affected about 33% of patients, and serious impairment impacted about 36% of patients. Moreover, PTSD in adults is also influenced by childhood trauma. In addition, as indicated, adult women have a higher frequency of PTSD at 5.2% compared to adult men at 1.8%. As a result, it is anticipated that the segment will continue to dominate during the projection period.

By Distribution Channel

The market is segmented into retail pharmacy, online pharmacy, hospital pharmacy, and others. In 2022, the retail pharmacy segment accounted for the largest revenue share owing to fact that retail pharmacies are convenient for the majority of prescriptions, particularly in the context of homecare. Treatment, control, and management of post-traumatic stress disorder require both short- and long-term assistance from pharmaceuticals, which promotes the expansion of retail pharmacies. The others segment is anticipated to exhibit a significant CAGR throughout the projection period. The availability of online pharmacy platform promotes buying convenience. The convenience and flexibility of home delivery have boosted the trend of online buying, which is fueling the segment’s growth and generating revenues.

Regional Markets

In 2022, North America region accounted for the highest revenue in the post-traumatic stress disorder market and is expected to maintain its dominance during the forecast period. This is attributed to the growing incidence of PTSD and expanding patient awareness of mental health. For instance, according to data and facts regarding PTSD, the frequency of the disorder among adults over the age of 18 in the U.S. was estimated to be 3.6%. The growth is being fueled by rising healthcare costs and the presence of significant companies in the region. Proactive government initiatives and advanced therapeutic choices, which are projected to see new approvals and launches during the forecast period, also support regional growth. Asia Pacific is predicted to experience the fastest growth rate in the upcoming years. The significant growth rate can be attributed to the increasing disorder burden and the growing number of individuals seeking medical attention for mental health. The market in the region is anticipated to be driven by positive improvements such government healthcare benefits, higher public awareness, and a greater desire among people to seek medical care.

Competitor Insights

Some of the key players operating in the post-traumatic stress disorder market are Merck KGaA, Bionomics, Aurobindo Pharma Limited, GlaxoSmithKline plc., Lupin Limited, Otsuka Pharmaceutical Development, Aptinyx, Jazz Pharmaceuticals, Pfizer, Inc., and AstraZeneca.

To achieve a competitive edge, these companies are implementing a variety of growth strategies. Strategic partnerships, alliances, and agreements with different businesses and research institutions are seen to be the main strategies used by companies in this sector.

• For instance, Mydecine Innovations Group Inc., Combat Stress, and King’s College London announced a contract to work together to treat PTSD with the psychotherapy drug psilocybin in January 2022.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including drug class, demographics, and distribution channel from 2023 to 2033.

Report Scope:

Segmentation: Post-traumatic Stress Disorder Treatment Market Report 2022 – 2033

Drug Class (Revenue, USD Million), 2022 – 2033

• Antipsychotics
• Antidepressants
• Anti-anxiety
• Others

Demographics (Revenue, USD Million), 2022 – 2033

• Geriatric
• Pediatric
• Adult

Distribution Channel (Revenue, USD Million), 2022 – 2033

• Retail Pharmacy
• Online Pharmacy
• Hospital Pharmacy
• Others

By Region (Revenue, USD Million), 2022 – 2033

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA